Yıl: 2021 Cilt: 56 Sayı: 4 Sayfa Aralığı: 339 - 343 Metin Dili: İngilizce DOI: 10.5152/TurkArchPediatr.2021.20165 İndeks Tarihi: 14-10-2021

Neurofibromatosis Type 1 in Children: A Single-Center Experience

Öz:
Objective: Neurofibromatosis (NF) is the most common autosomal dominantly inherited neurocutaneoussyndrome. The characteristic features of NF type 1 (NF-1) are café au lait spots,axillary and inguinal freckling, peripheral neurofibromas, optic pathway glioma, and Lischnodules. The present study aimed to analyze the clinical features of children with NF-1.Materials and Methods: In this study, the children with NF-1 diagnosed and followed-up inour center between 2000 and 2020 were retrospectively evaluated. Demographic and clinicalfeatures of patients were defined.Results: The study group consisted of 52 patients. Of those, 25 were boys and 27 were girls. Thechildren’s median age at diagnosis was 5.9 years (1-15.8). Café au lait (CAL) spots and axillary/inguinal freckling were observed in 50 and 24 patients, respectively. Neurofibroma waspresent in 22 cases. Ten of the cohort had optic gliomas, and 39 of them had cranial hamartomas.Orthopedic complications such as scoliosis, tibial pseudoarthrosis, and osteoporosis wereobserved in 13 patients. Eleven children had neurocognitive disorders.Conclusions: Early diagnosis is important in neurofibromatosis to prevent the complications ofthe disease. Also, neurological development and secondary malignancy follow-up should bedone carefully in this group of patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Kresak JL, Walsh M. Neurofibromatosis: a review of NF1, NF2, and schwannomatosis. J Pediatr Genet. 2016;5:98-104. [CrossRef]
  • 2. Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2018;148:799-811. [CrossRef]
  • 3. Ly KI, Blakeley JO. The diagnosis and management of neurofibromatosis type 1. Med Clin North Am. 2019;103:1035-1054. [CrossRef]
  • 4. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834-843. [CrossRef]
  • 5. Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75-86. [CrossRef]
  • 6. Gutmann DH. Exploring the genetic basis for clinical variation in neurofibromatosis type 1. Expert Rev Neurother. 2016;16:999-1001. [CrossRef]
  • 7. Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol. 2013;115:939-955. [CrossRef]
  • 8. McKeever K, Shepherd CW, Crawford H, Morrison PJ. An epidemiological, clinical, and genetic survey of neurofibromatosis type 1 in children under sixteen years of age. Ulster Med J. 2008;77:160-163.
  • 9. Atik T, Çoğulu Ö, Özkınay F. Nörofibromatozis tip 1’de genetik danışmanlık. J Pediatr Res. 2014;1:152-154.
  • 10. Valero MC, Martín Y, Hernández-Imaz E, et al. A highly sensitive genetic protocol to detect NF1 mutations. J Mol Diagn. 2011;13:113- 122. [CrossRef]
  • 11. Upadhyaya M, Cooper DN. Neurofibromatosis type 1. From Genotype to Phenotype. Oxford: Bios Scientific; 1998:21-38.
  • 12. Abeliovich D, Gelman-Kohan Z, Silverstein S, et al. Familial café- Au-lait spots: a variant of neurofibromatosis type 1. J Med Genet. 1995;32:985-986. [CrossRef]
  • 13. Miettinen MM, Antonescu CR, Fletcher CDM, et al. Hıstopathologıc evaluatıon of atypıcal neurofıbromatous tumors and theır transformatıon ınto malıgnant perıpheral nerve sheath tumor ın neurofıbromatosıs 1 patıents—a consensus overvıew. Hum Pathol. 2017;67:1-10. [CrossRef]
  • 14. Rad E, Tee AR. Neurofibromatosis type 1: fundamental insights into cell signaling and cancer. Semin Cell Dev Biol. 2016;52:39-46. [CrossRef]
  • 15. McGaughran JM, Harris DI, Donnai D, et al. A clinical study of type 1 neurofibromatosis in northwest England. J Med Genet. 1999;36:197-203.
  • 16. Kinori M, Hodgson N, Zeid JL. Ophthalmic manifestations in neurofibromatosis type 1. Surv Ophthalmol. 2018;63:518-533. [CrossRef]
  • 17. Abdolrahimzadeh S, Plateroti AM, Recupero SM, Lambiase A. An update on the ophthalmologic features in the phakomatoses. J Ophthalmol. 2016;2016:3043026. [CrossRef]
  • 18. Duffner PK, Cohen ME, Seidel FG, Shucard DW. The significance of MRI abnormalities in children with neurofibromatosis. Neurology. 1989;39:373-378. [CrossRef]
  • 19. Çarman KB, Coşkun Yarar C, Ekici A, et al. Nörofibromatozis tip 1: 49 olgunun değerlendirilmesi. Haydarpasa Numune Med J. 2017;57:157-160.
  • 20. Listernick R, Louis DN, Packer RJ, Gutmann DH. Optic pathways glioma in children with neurofibromatosis type 1: a consensus statement from the Optic Pathway Glioma Task Force. Ann Neurol. 1997;41:143-149. [CrossRef]
  • 21. Parazzini C, Triulzi F, Bianchini E, et al. Spontaneous involution of optic pathway lesions in neurofibromatosis type 1: serial contrast evaluation. Am J Neuroradiol. 1995;16:1711-1718.
  • 22. Freret ME, Gutmann DH. Understanding vision loss from optic pathway glioma in neurofibromatosis type 1. J Neurosci Res. 2019;97:45-56. [CrossRef]
  • 23. Campen CJ, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1. J Child Neurol. 2018;33:73-81. [CrossRef]
  • 24. Peltonen S, Kallionpää RA, Rantanen M, et al. Pediatric malignancies in neurofibromatosis type 1: a population‐based cohort study. Int J Cancer. 2019;145:2926-2932. [CrossRef]
  • 25. Torres Nupan MM, Velez Van Meerbeke A, López Cabra CA, Herrera Gomez PM. Cognitive and behavioral disorders in children with neurofibromatosis type 1. Front Pediatr. 2017;5:227. [CrossRef]
  • 26. Acosta MT, Bearden CE, Xavier F, et al. The learning disabilities network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am J Med Genet A. 2012;158A:2225-2232.
  • 27. Gresham FM, MacMillan DL, Bocian KM. Learning disabilities, low achievement, and mild mental retardation: more alike than different? J Learn Disabil. 1996;29:570-581. [CrossRef]
  • 28. Leppävirta J, Kallionpää RA, Uusitalo E, et al. Congenital anomalies in neurofibromatosis 1: a retrospective register-based total population study. Orphanet J Rare Dis. 2018;13:5. [CrossRef]
  • 29. Lammert M, Friedman JM, Roth HJ, et al. Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1. J Med Genet. 2006;43:810-813. [CrossRef]
  • 30. Schnabel C, Jan KJ, Friedman M, et al. Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study. Joint Bone Spine. 2013;3:315-319.
APA Kacar A, Kılınç b, Çınar Özel S, ocak s, Gunes N, Uludag Alkaya D, Tüysüz B, Apak H, CELKAN T (2021). Neurofibromatosis Type 1 in Children: A Single-Center Experience. , 339 - 343. 10.5152/TurkArchPediatr.2021.20165
Chicago Kacar Ayse Gonca,Kılınç burcu,Çınar Özel Simge,ocak suheyla,Gunes Nilay,Uludag Alkaya Dilek,Tüysüz Beyhan,Apak Hilmi,CELKAN TÜLIN TIRAJE Neurofibromatosis Type 1 in Children: A Single-Center Experience. (2021): 339 - 343. 10.5152/TurkArchPediatr.2021.20165
MLA Kacar Ayse Gonca,Kılınç burcu,Çınar Özel Simge,ocak suheyla,Gunes Nilay,Uludag Alkaya Dilek,Tüysüz Beyhan,Apak Hilmi,CELKAN TÜLIN TIRAJE Neurofibromatosis Type 1 in Children: A Single-Center Experience. , 2021, ss.339 - 343. 10.5152/TurkArchPediatr.2021.20165
AMA Kacar A,Kılınç b,Çınar Özel S,ocak s,Gunes N,Uludag Alkaya D,Tüysüz B,Apak H,CELKAN T Neurofibromatosis Type 1 in Children: A Single-Center Experience. . 2021; 339 - 343. 10.5152/TurkArchPediatr.2021.20165
Vancouver Kacar A,Kılınç b,Çınar Özel S,ocak s,Gunes N,Uludag Alkaya D,Tüysüz B,Apak H,CELKAN T Neurofibromatosis Type 1 in Children: A Single-Center Experience. . 2021; 339 - 343. 10.5152/TurkArchPediatr.2021.20165
IEEE Kacar A,Kılınç b,Çınar Özel S,ocak s,Gunes N,Uludag Alkaya D,Tüysüz B,Apak H,CELKAN T "Neurofibromatosis Type 1 in Children: A Single-Center Experience." , ss.339 - 343, 2021. 10.5152/TurkArchPediatr.2021.20165
ISNAD Kacar, Ayse Gonca vd. "Neurofibromatosis Type 1 in Children: A Single-Center Experience". (2021), 339-343. https://doi.org/10.5152/TurkArchPediatr.2021.20165
APA Kacar A, Kılınç b, Çınar Özel S, ocak s, Gunes N, Uludag Alkaya D, Tüysüz B, Apak H, CELKAN T (2021). Neurofibromatosis Type 1 in Children: A Single-Center Experience. Turkish archives of pediatrics (Online), 56(4), 339 - 343. 10.5152/TurkArchPediatr.2021.20165
Chicago Kacar Ayse Gonca,Kılınç burcu,Çınar Özel Simge,ocak suheyla,Gunes Nilay,Uludag Alkaya Dilek,Tüysüz Beyhan,Apak Hilmi,CELKAN TÜLIN TIRAJE Neurofibromatosis Type 1 in Children: A Single-Center Experience. Turkish archives of pediatrics (Online) 56, no.4 (2021): 339 - 343. 10.5152/TurkArchPediatr.2021.20165
MLA Kacar Ayse Gonca,Kılınç burcu,Çınar Özel Simge,ocak suheyla,Gunes Nilay,Uludag Alkaya Dilek,Tüysüz Beyhan,Apak Hilmi,CELKAN TÜLIN TIRAJE Neurofibromatosis Type 1 in Children: A Single-Center Experience. Turkish archives of pediatrics (Online), vol.56, no.4, 2021, ss.339 - 343. 10.5152/TurkArchPediatr.2021.20165
AMA Kacar A,Kılınç b,Çınar Özel S,ocak s,Gunes N,Uludag Alkaya D,Tüysüz B,Apak H,CELKAN T Neurofibromatosis Type 1 in Children: A Single-Center Experience. Turkish archives of pediatrics (Online). 2021; 56(4): 339 - 343. 10.5152/TurkArchPediatr.2021.20165
Vancouver Kacar A,Kılınç b,Çınar Özel S,ocak s,Gunes N,Uludag Alkaya D,Tüysüz B,Apak H,CELKAN T Neurofibromatosis Type 1 in Children: A Single-Center Experience. Turkish archives of pediatrics (Online). 2021; 56(4): 339 - 343. 10.5152/TurkArchPediatr.2021.20165
IEEE Kacar A,Kılınç b,Çınar Özel S,ocak s,Gunes N,Uludag Alkaya D,Tüysüz B,Apak H,CELKAN T "Neurofibromatosis Type 1 in Children: A Single-Center Experience." Turkish archives of pediatrics (Online), 56, ss.339 - 343, 2021. 10.5152/TurkArchPediatr.2021.20165
ISNAD Kacar, Ayse Gonca vd. "Neurofibromatosis Type 1 in Children: A Single-Center Experience". Turkish archives of pediatrics (Online) 56/4 (2021), 339-343. https://doi.org/10.5152/TurkArchPediatr.2021.20165